LA ROCHE POSAY Lipikar Baume AP+M

It's the perfect body balm to get rid of severely dry, itchy, and eczema-prone skin in babies, children, and adults. Clinically proven, Lipikar Balm AP+M reduces itching by half, provides immediate relief, and reduces the frequency of eczema and severe dryness flare-ups. The new AP+M triple-action formula has enhanced anti-scratch and anti-relapse efficacy and rebalances the skin's microbiome. It replenishes essential skin lipids to strengthen its moisture barrier and provides 48-hour long-lasting hydration. It can be used on the face, hands, and body and is suitable for adults, children, and babies from 2 weeks of age, for year-round use.

The soothing balm absorbs quickly into the skin and is non-greasy with a non-sticky finish, leaving skin soft and comforted from sensitivities.

La Roche-Posay research has shown that to provide lasting relief for eczema-prone skin, it is necessary to rebalance its microbiome, the living, invisible ecosystem of bacteria on the skin. This knowledge inspired the formula of Lipikar Balm AP+M, which provides triple-action efficacy for atopic skin: 1) on the microbial barrier to rebalance the skin microbiome; 2) on the skin's moisture barrier to reduce transepidermal water loss; and 3) on the immune barrier to decrease inflammation, helping to reduce pain, itching, and flare-ups. It immediately soothes the skin and reduces scratching. With its anti-flare-up efficacy, it spaces out severe dryness flare-ups, nourishes the skin, and helps restore the skin's moisture barrier.

It reduces the frequency of severe dryness outbreaks.
Immediate pain relief, reduces sensations of pain
2 times less itching
2 times less relapse*
48-hour hydration
Rebalance your skin's microbiome
Reduces areas of dry and rough skin
Clinical results of routine use with Lipikar Syndet AP+**:

41% reduction in itching sensations
42% decrease in sleep loss
69% improvement in quality of life
*3,787 patients, with continuous use, 1 application/day, severe dryness peaks are spaced out.

**Clinical study in 51 subjects (children and adults) for 2 weeks.